KR20160108554A - 안질환 치료용 조성물 및 치료방법 - Google Patents

안질환 치료용 조성물 및 치료방법 Download PDF

Info

Publication number
KR20160108554A
KR20160108554A KR1020167022741A KR20167022741A KR20160108554A KR 20160108554 A KR20160108554 A KR 20160108554A KR 1020167022741 A KR1020167022741 A KR 1020167022741A KR 20167022741 A KR20167022741 A KR 20167022741A KR 20160108554 A KR20160108554 A KR 20160108554A
Authority
KR
South Korea
Prior art keywords
eye
compound
disease
macular degeneration
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167022741A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 데일리
로버트 쉘비츠
Original Assignee
아케비아 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아케비아 테라퓨틱스 인코포레이티드 filed Critical 아케비아 테라퓨틱스 인코포레이티드
Publication of KR20160108554A publication Critical patent/KR20160108554A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y10S514/912—
    • Y10S514/913—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167022741A 2014-01-23 2015-01-23 안질환 치료용 조성물 및 치료방법 Withdrawn KR20160108554A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461930811P 2014-01-23 2014-01-23
US61/930,811 2014-01-23
PCT/US2015/012634 WO2015112831A1 (en) 2014-01-23 2015-01-23 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
KR20160108554A true KR20160108554A (ko) 2016-09-19

Family

ID=53681968

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167022741A Withdrawn KR20160108554A (ko) 2014-01-23 2015-01-23 안질환 치료용 조성물 및 치료방법

Country Status (11)

Country Link
US (1) US20160339005A1 (enExample)
EP (1) EP3096617A4 (enExample)
JP (1) JP2017503835A (enExample)
KR (1) KR20160108554A (enExample)
CN (1) CN106132201A (enExample)
AU (1) AU2015209264A1 (enExample)
CA (1) CA2937349A1 (enExample)
IL (1) IL246791A0 (enExample)
MX (1) MX2016009331A (enExample)
RU (1) RU2016133980A (enExample)
WO (1) WO2015112831A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180092886A (ko) 2017-02-09 2018-08-20 주식회사 유스바이오팜 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
KR20180138109A (ko) 2017-06-20 2018-12-28 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
US11331326B2 (en) 2016-09-30 2022-05-17 Amicogen Pharma Inc. Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE485264T1 (de) 2006-06-26 2010-11-15 Warner Chilcott Co Llc Prolylhydroxylase-hemmer und verfahren zu ihrer anwendung
NO2686520T3 (enExample) 2011-06-06 2018-03-17
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
MX374909B (es) 2015-04-01 2025-03-06 Akebia Therapeutics Inc El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.
US11064685B2 (en) * 2017-02-27 2021-07-20 Regeneron Pharmaceuticals, Inc. Non-human animal models of retinoschisis
CA3055985A1 (en) * 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
WO2018202865A1 (en) * 2017-05-05 2018-11-08 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
WO2018232227A1 (en) * 2017-06-15 2018-12-20 The Trustees Of Columbia University In The City Of New York Treatment of neurodegeneration via reprogramming metabolism by inhibiting phd
MX2020011535A (es) * 2018-05-01 2020-11-24 Chibi Inc Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
IL278533B1 (en) 2018-05-09 2025-10-01 Akebia Therapeutics Inc Process for the preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
CN112805023A (zh) * 2018-08-21 2021-05-14 加州理工学院 无渗漏或最小渗漏的脉络膜或视网膜血管再生
US12239644B2 (en) 2018-11-02 2025-03-04 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of macular degeneration
JP7280353B2 (ja) * 2018-11-02 2023-05-23 キョンブク ナショナル ユニバーシティ インダストリー－アカデミック コーオペレーション ファウンデーション 黄斑変性予防又は治療用組成物
AU2019382044B2 (en) * 2018-11-14 2025-07-17 Smilebiotek Zhuhai Limited Animal models, screening methods, and treatment methods for intraocular diseases or disorders
CN111308001B (zh) * 2018-12-11 2024-11-29 上海市第一人民医院 人黄斑新生血管性疾病的代谢标记物及其应用
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
AU2021217358A1 (en) * 2020-02-06 2022-09-08 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
EP4322985A4 (en) * 2021-04-13 2025-02-19 Unity Biotechnology, Inc. METHODS OF TREATMENT OF RETINAL VASCULOPATHIES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19650215A1 (de) * 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2007101204A1 (en) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
ATE485264T1 (de) * 2006-06-26 2010-11-15 Warner Chilcott Co Llc Prolylhydroxylase-hemmer und verfahren zu ihrer anwendung
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
CA2837560C (en) * 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
AU2014348523B2 (en) * 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11331326B2 (en) 2016-09-30 2022-05-17 Amicogen Pharma Inc. Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid
KR20180092886A (ko) 2017-02-09 2018-08-20 주식회사 유스바이오팜 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
KR20190135955A (ko) 2017-02-09 2019-12-09 주식회사 유스바이오팜 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
KR20220000881A (ko) 2017-02-09 2022-01-04 주식회사 아미코젠파마 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
KR20180138109A (ko) 2017-06-20 2018-12-28 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물

Also Published As

Publication number Publication date
US20160339005A1 (en) 2016-11-24
MX2016009331A (es) 2016-10-26
CA2937349A1 (en) 2015-07-30
EP3096617A1 (en) 2016-11-30
EP3096617A4 (en) 2017-09-13
WO2015112831A8 (en) 2016-09-01
AU2015209264A1 (en) 2016-08-04
RU2016133980A3 (enExample) 2018-10-26
CN106132201A (zh) 2016-11-16
JP2017503835A (ja) 2017-02-02
WO2015112831A1 (en) 2015-07-30
IL246791A0 (en) 2016-08-31
RU2016133980A (ru) 2018-03-01

Similar Documents

Publication Publication Date Title
KR20160108554A (ko) 안질환 치료용 조성물 및 치료방법
US12357565B2 (en) Ocular implant containing a tyrosine kinase inhibitor
JP2024069363A (ja) 翼状片を治療するための組成物及び方法
JP6427497B2 (ja) 眼疾患の治療剤又は予防剤
JP2021509912A (ja) 眼疾患を治療するための方法
TWI755356B (zh) 含檸檬酸酯之緩釋劑之用途
JP2000514402A (ja) Ｖｅｇｆに関連する目の病気に関する治療処置
JP7730816B2 (ja) 過剰血管新生に関連する眼疾患を治療する化合物
JP2020117522A (ja) 徐放性医薬組成物
WO2009023411A1 (en) Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases
US20140302009A1 (en) Medicinal Agent for Prevention or Treatment of Diseases Associated with Intraocular Neovascularization and/or Intraocular Vascular Hyperpermeability
JP2020513004A (ja) Ｃｃｒ３阻害剤を使用した網膜関連疾患を治療するための方法および組成物
US20170027936A1 (en) Abl1 inhibitor for treating and preventing ocular neovascularisation
JP2022547537A (ja) 眼疾患を治療するための方法
JP6835836B2 (ja) 脈絡膜血管新生の処置のための方法及び医薬組成物
CN108064171A (zh) 含有多肽的医药组合物
WO2020203822A1 (ja) 血管新生を伴う網膜疾患の治療又は予防のための併用医薬

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160819

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid